Explore Poster titles that will be presented at the 2022 IKCS: North America meeting. Posters will be available in-person and online. Posters will be hung up by 12:00 PM on Friday, November 4 and will remain hanging until the meeting ends on the afternoon of Saturday, November 5.

Join a Poster Walk!

Poster Walks are small group tours of the posters where participants can ask questions to presenters, discuss research with other attendees, and glean insights from Faculty.

Poster Walks will take place in-person and virtually on Friday, November 4 from 5:30 PM- 6:15 PM CDT.

  • In-person Poster Walk Leaders: Sumanta K. Pal, FASCO, City of Hope and Shawn Dason, MD, Ohio State University Medical Center
  • Virtual Poster Walk Leaders: Bradley McGregor, MD, Dana-Farber Cancer Institute and Phillip M. Pierorazio, MD, Penn Presbyterian Medical Center

Posters by Topic:

Late-breaking Data Abstracts: Poster Board E2
Regular Abstracts: Poster Boards A1- E1; E3- E7
Case Reports: Poster Board E8
Trials in Progress Abstracts: Poster Boards F1- F7
Basic Science: Poster Boards A1- A2
Imaging: Poster Board A3
Patient-reported Outcomes: Poster Board A5
Post-treatment Surveillance: Poster Boards A6- A7
Quality of Care and Quality Improvement: Poster Boards A8- B3
Real-World Evidence: Poster Boards B4- C1
Survivorship: Poster Boards C2- C3
Therapeutics (Local- Primary and Metastases): Poster Boards C4- C5
Therapeutics (Systemic- Radiation Therapy, Ablation, Surgery, Interventional Radiology, Urology, Medical Oncology, etc.): Poster Boards C6- E1; F1- F7
Treatment Toxicities and Symptom Management: Poster Boards E2- E3
Tumor Biology, Biomarkers, and Pathology: Poster Boards E4- E7
Other: Poster Boards A4, E8

Board A1: Abstract 9: DNA methylation-based tumor microenvironment deconvolution in clear cell renal cell carcinoma reveals significant survival association with specific cell types
Presenter: Ze Zhang

Board A2: Abstract 10: Epigenetic Dysregulation Activates the Oncogenic Dicarboxylic Amino Acid Transporter SLC1A1 in ccRCC
Presenter: Abhishek Chakraborty

Board A3: Abstract 11: Differentiation Clear Cell Renal Cell Carcinoma from Other Common Malignant and Benign Renal Masses on Multiphasic MRI: A Likert Based Multireader Analysis
Presenter: Chuthaporn Surawech

Board A4: Abstract 12: Outcomes of active surveillance for young and healthy patients with small renal masses
Presenter: Muammer Altok

Board A5: Abstract 13: The Role of Exercise on the Physical and Mental Health of Kidney Cancer Patients and Survivors
Presenter: Daniel Roberson

Board A6: Abstract 14: Risk factors for end stage renal disease after treatment of renal cell carcinoma
Presenter: Sven Lundstam

Board A7: Abstract 15: Survival Outcomes Following Adoption of Risk-Adjusted AUA Surveillance Guidelines After Partial Nephrectomy
Presenter: Wesley Yip

Board A8: Abstract 16: Artificial intelligence modelling to predict the risk of cardiotoxicity among renal cell carcinoma  patients treated with vascular endothelial growth factor receptors tyrosine kinase inhibitors.
Presenter: Hesham Yasin

Board B1: Abstract 17: Kidney cancer clinical trials: a decision aid for patients and clinicians
Presenter: Rachel Giles (Alternate Presenter: Eric Jonasch)

Board B2: Abstract 18: Non-Index vs Index Readmissions Following Radical Nephrectomy: Causes, Costs, and Outcomes
Presenter: Shiva Balasubramanian

Board B3: Abstract 19: Non-Index vs Index Readmissions Following Partial Nephrectomy: Causes, Costs, and Outcomes
Presenter: Shiva Balasubramanian

Board B4: Abstract 20: Real-world Clinical Outcomes of Patients (pts) with Metastatic Renal Cell Carcinoma (mRCC) Receiving Pembrolizumab + Axitinib (P+A) vs Ipilimumab + Nivolumab (I+N)
Presenter: Neil J. Shah

Board B5: Abstract 21: Short-Term Outcomes of Active Surveillance for Small Renal Masses in Patients With End-Stage Renal Disease and Immunosuppression
Presenter: Zoe Gan

Board B6: Abstract 22: Healthcare resource utilization (HCRU) and costs in metastatic renal cell carcinoma (mRCC) patients (pts) receiving first-line (LOT1) pembrolizumab + axitinib (P+A) or ipilimumab + nivolumab (I+N)
Presenter: Neil J. Shah

Board B7: Abstract 23: Real-world Assessment of Changing Treatment Patterns and sequence for patients with Metastatic Renal Cell Carcinoma (mRCC) in the first-line (1L) setting
Presenter: Neil J. Shah

Board B8: Abstract 24: Depth of response associated with first-line immunotherapy-based combinations in metastatic clear cell renal cell carcinoma.
Presenter: Kelly Fitzgerald

Board C1: Abstract 25: Clinical manifestations of Birt-Hogg-Dube Syndrome in a large clinical cohort
Presenter: Raju Chelluri

Board C2: Abstract 26: Role of Histology in Influencing Outcomes after Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma
Presenter: Pranjal Agrawal

Board C3: Abstract 27: Cytoreductive Nephrectomy with Concomitant IVC Tumor Thrombectomy in Metastatic Renal Cell Carcinoma
Presenter: Pranjal Agrawal

Board C4: Abstract 28: Treatment decisions among patients newly diagnosed with clinical T1 renal masses
Presenter: Kathryn Gessner

Board C5: Abstract 29: Cytoreductive nephrectomy (CN) for patients with metastatic sarcomatoid and/or rhabdoid (S/R) renal cell carcinoma (RCC) treated with immune checkpoint therapy (ICT)
Presenter: Andrew Hahn

Board C6: Abstract 30: Treatment-free survival (TFS) in patients with advanced renal cell carcinoma (aRCC) treated with nivolumab and ipilimumab (NIVO/IPI) versus sunitinib (SUN): 60-month update of Checkmate 214
Presenter: Charlene Mantia

Board C7: Abstract 31: Updated efficacy of lenvatinib + pembrolizumab versus sunitinib in patients with advanced renal cell carcinoma (aRCC) in the CLEAR study
Presenter: Camillo G. Porta (Alternate Presenter: Bradley McGregor)

Board C8: Abstract 32: Efficacy and safety of nivolumab plus ipilimumab versus sunitinib for first-line treatment of patients with advanced sarcomatoid renal cell carcinoma (sRCC) in the phase 3 CheckMate 214 trial with extended 5-year minimum follow-up
Presenter: Nazir Tannir

Board D1: Abstract 33: Long-term PFS from TIVO-3: Tivozanib (TIVO) vs sorafenib (SOR) in relapsed/refractory (R/R) advanced RCC
Presenter: Michael Atkins

Board D2: Abstract 34: Characterization of Patients Undergoing Consolidative Nephrectomy after Immunotherapy
Presenter: Stephen Reese

Board D3: Abstract 35: Activity of tivozanib in non-clear cell renal cell carcinoma (nccRCC): Subgroup analysis from a phase 2 randomized discontinuation trial
Presenter: Pedro Barata

Board D4: Abstract 36: Impact of subsequent therapies in patients with advanced renal cell carcinoma (aRCC) receiving lenvatinib plus pembrolizumab or sunitinib in the CLEAR study
Presenter: Martin H. Voss

Board D5: Abstract 37: A randomized phase 2 study with a cell-based immune primer plus sunitinib versus sunitinib aone in metastatic Renal Cell Carcinoma.
Presenter: Börje Ljungberg

Board D6: Abstract 38: Association between depth of response (DepOR) and clinical outcomes: exploratory analysis in patients with previously untreated advanced renal cell carcinoma (aRCC) in CheckMate 9ER
Presenter: Andrea Apolo (Alternate Presenter: Bernard Escudier)

Board D7: Abstract 39: Maturation of overall survival (OS) in TIVO-3 with long-term follow-up
Presenter: Brian Rini

Board D8: Abstract 40: Phase 1 trial of combination therapy with avelumab and cabozantinib in patients with newly diagnosed metastatic clear cell renal cell carcinoma
Presenter: Haoran Li

Board E1: Abstract 41: Efficacy of nivolumab plus ipilimumab in T1aN0M0 renal cell carcinoma patients ineligible for surgery and ablation
Presenter: Ilya Tsimafeyeu

Board E2: Abstract 42: Peripheral blood biomarkers to predict serious immune related adverse events in patients with metastatic renal cell carcinoma undergoing treatment with immune checkpoint blockade
Presenter: John Leppert

Board E3: Abstract 43: Risk of Thromboembolism in Patients Receiving Immunotherapy-Based Combinations for Metastatic Renal Cell Carcinoma
Presenter: James Schuster

Board E4: Abstract 44: NF2-Mutant Renal Cell Carcinoma: A Comprehensive Characterization of a Lethal Unclassified Renal Cell Carcinoma
Presenter: Stephen Reese

Board E5: Abstract 45: Metagenomic analysis of the gut microbiome in metastatic renal cell carcinoma patients with sarcopenia
Presenter: Neal Chawla

Board E6: Abstract 46: Prospective evaluation of mutation concordance between standard-of-care renal mass biopsy and nephrectomy specimens in small renal masses
Presenter: Kathryn Gessner

Board E7: Abstract 47: Epigenetic, transcriptional, and compositional shifts in clear cell renal cell carcinomas
Presenter: Lucas Salas

Board E8: Abstract 48: A Case of Metastatic Renal Cell Carcinoma to The Maxillary Sinus Initially Presenting as Recurrent Epistaxis
Presenter: Justin Mehr

Board F1: Abstract 49: A randomized trial of radium-223 (Ra-223) dichloride and cabozantinib in patients (pts) with advanced renal cell carcinoma (RCC) with bone metastases (RADICAL / Alliance A031801)
Presenter: Rana McKay

Board F2: Abstract 50: TiNivo-2: A Phase 3 Study to Compare Tivozanib+Nivolumab to Tivozanib Monotherapy in Patients with Renal Cell Carcinoma (RCC) Who Have Progressed Following ≤2 Lines of Therapy including an Immune Checkpoint Inhibitor (ICI)
Presenter: Toni Choueri

Board F3: Abstract 51: A phase II study of lenvatinib plus everolimus versus cabozantinib in patients with metastatic renal cell carcinoma (mRCC) that progressed on a PD-1/PD-L1 checkpoint inhibitor (LenCabo)
Presenter: Andrew Hahn

Board F4: Abstract 52: LITESPARK-011: a randomized, phase 3 study of belzutifan plus lenvatinib versus cabozantinib after anti–PD-1/PD-L1 therapy in patients with advanced renal cell carcinoma
Presenter: Daniel YC Heng

Board F5: Abstract 53: Phase 2 trial for sequential treatment after cabozantinib progression in  metastatic renal cell carcinoma (Seq-Cabo)
Presenter: Qian Qin

Board F6: Abstract 54: APART – A Phase 2 trial of Axitinib, Palbociclib and Avelumab as  advanced Clear Cell Renal Cell Carcinoma (ccRCC) Therapy
Presenter: Stephanie Berg

Board F7: Abstract 55: A pilot study of the immunomodulatory agent acarbose in combination with standard therapy in metastatic renal cell carcinoma (RCC)
Presenter: Arnab Basu